Guardant Health, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a GH research report →
About the company
Guardant Health, Inc. , established in Redwood City, California, in 2011, is a precision oncology company that delivers a range of diagnostic blood tests, comprehensive data sets, and advanced analytical solutions both within the United States and internationally. For patients with advanced-stage cancer, the company's core offerings include several liquid biopsy-based tests such as Guardant360 (available in LDT and CDx versions) and GuardantOMNI.
- CEO
- Helmy Eltoukhy
- IPO
- 2018
- Employees
- 1,999
- HQ
- Palo Alto, CA, US
Price Chart
- Market Cap
- $17.17B
- P/E
- -39.23
- P/S
- 15.89
- P/B
- -93.85
- EV/EBITDA
- -45.73
- Div Yield
- 0.00%
- Gross Margin
- 64.90%
- Op Margin
- -41.43%
- Net Margin
- -40.10%
- ROE
- 184.27%
- ROIC
- -27.03%
- Revenue
- $982.02M · 32.88%
- Net Income
- $-416,277,000 · 4.61%
- EPS
- $-3.32 · 6.74%
- Op Income
- $-436,298,000
- FCF YoY
- 15.23%
- 52W High
- $135.00
- 52W Low
- $40.35
- 50D MA
- $102.83
- 200D MA
- $92.63
- Beta
- 1.62
- Avg Volume
- 2.18M
Get TickerSpark's AI analysis on GH
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 10, 26 | Kalia Kumud | sell | 5,000 |
| Jun 5, 26 | Eltoukhy Helmy | sell | 49,716 |
| Jun 5, 26 | Eltoukhy Helmy | sell | 33,843 |
| Jun 5, 26 | Eltoukhy Helmy | sell | 1,100 |
| Jun 5, 26 | Eltoukhy Helmy | sell | 13,787 |
| Jun 5, 26 | Eltoukhy Helmy | sell | 554 |
| Jun 5, 26 | Eltoukhy Helmy | sell | 900 |
| Jun 5, 26 | Eltoukhy Helmy | sell | 100 |
| Jun 5, 26 | Bell Michael Brian | sell | 2,000 |
| Jun 4, 26 | Krognes Steve E. | sell | 9,294 |
Our GH coverage
Recent articles, reports, and earnings notes.
Want a deeper read on GH?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Similar companies
Peers in the same neighborhood.